Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Marimed (MRMD) EBITDA (2016 - 2025)

Historic EBITDA for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $1.6 million.

  • Marimed's EBITDA rose 1888.48% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $724000.0, marking a year-over-year decrease of 8924.7%. This contributed to the annual value of $2.9 million for FY2024, which is 7975.67% down from last year.
  • Marimed's EBITDA amounted to $1.6 million in Q3 2025, which was up 1888.48% from $1.1 million recorded in Q2 2025.
  • Marimed's EBITDA's 5-year high stood at $12.0 million during Q2 2021, with a 5-year trough of -$1.2 million in Q4 2024.
  • For the 5-year period, Marimed's EBITDA averaged around $3.5 million, with its median value being $3.1 million (2022).
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 59868.15% in 2021, then plummeted by 14832.02% in 2024.
  • Over the past 5 years, Marimed's EBITDA (Quarter) stood at $1.2 million in 2021, then soared by 156.77% to $3.1 million in 2022, then fell by 21.95% to $2.4 million in 2023, then tumbled by 148.32% to -$1.2 million in 2024, then surged by 237.25% to $1.6 million in 2025.
  • Its EBITDA stands at $1.6 million for Q3 2025, versus $1.1 million for Q2 2025 and -$851000.0 for Q1 2025.